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The treatment of cells with histone deacetylase inhibitors (HDACi) was reported to reveal the acetylation of
STAT1 at lysine 410 and lysine 413 (O. H. Kra¨mer et al., Genes Dev. 20:473–485, 2006). STAT1 acetylation was
proposed to regulate apoptosis by facilitating binding to NF-B and to control immune responses by sup-
pressing STAT1 tyrosine phosphorylation, suggesting that STAT1 acetylation is a central mechanism by which
histone deacetylase inhibitors ameliorate inflammatory diseases (O. H. Kra¨mer et al., Genes Dev. 23:223–235,
2009). Here, we show that the inhibition of deacetylases had no bearing on STAT1 acetylation and did not
diminish STAT1 tyrosine phosphorylation. The glutamine mutation of the alleged acetylation sites, claimed to
mimic acetylated STAT1, similarly did not diminish the tyrosine phosphorylation of STAT1 but precluded its
DNA binding and nuclear import. The defective transcription activity of this mutant therefore cannot be
attributed to STAT1 acetylation but rather to the inactivation of the STAT1 DNA binding domain and its
nuclear import signal. Experiments with respective cDNAs provided by the authors of the studies mentioned
above confirmed the results reported here, further questioning the validity of the previous data. We conclude
that the effects and potential clinical benefits associated with histone deacetylase inhibition cannot be ex-
plained by promoting the acetylation of STAT1 at lysines 410 and 413.
The inactivation of histone deacetylases by chemicals
termed histone deacetylase inhibitors (HDACi), such as tri-
chostatin A (TSA) and valproic acid (VPA), has found impor-
tant clinical applications ranging from psychiatry to cancer and
inflammation (1, 13). Best characterized are their effects on the
acetylation of histones resulting in altered chromatin accessi-
bility and, hence, gene transcription (7). Additionally, there is
a growing number of nonhistone proteins whose acetylation
has been reported to be increased by HDACi (13), including
the transcription factor STAT1 (22, 23), which is indispensable
for the actions of interferons (IFNs) (8). The IFNs have key
roles in antiviral and antigrowth responses and in modulating
immunity, essentially all of which entail the activation of
STAT1 by the phosphorylation of Tyr701 (8, 39). STAT1 ac-
tivation has important functional consequences. It transforms
STAT1 into a sequence-specific DNA binding protein and
transcription activator (24). Contrary to unphosphorylated
STAT1, which is a nucleocytoplasmic shuttling protein, phos-
phorylated STAT1 can only enter the nucleus (42). In further
contrast to unphosphorylated STAT1, the nuclear import of
the activated molecule is dependent on metabolic energy and
importin transport factors (42). Importin recruitment requires
a nuclear localization signal (NLS) situated in the DNA bind-
ing domain (Fig. 1), which was named the dimer-specific NLS
(dsNLS) (29). However, as it is now known that STAT1 is
dimeric before activation, we propose renaming it NLS of
phosphorylated STAT1 (pNLS). Since activated STAT1 needs
to be dephosphorylated before nucleocytoplasmic shuttling
can resume, activation is associated with the transient trapping
of STAT1 in the nucleus, which is readily apparent as nuclear
accumulation in interferon-stimulated cells (30).
Interferon signaling was demonstrated to require deacety-
lase activity, but initial studies did not establish a direct link to
STAT1 acetylation or phosphorylation (5, 33). Nonetheless,
micromolar concentrations of the deacetylase inhibitor TSA
were shown to decrease the phosphorylation of STAT1; how-
ever, this effect was found to be indirect, as the STAT1-acti-
vating JAK tyrosine kinases were inhibited by HDACi (19, 20).
Nanomolar concentrations of TSA, in contrast, were shown to
reduce the expression of IFN-regulated genes without affecting
STAT1 phosphorylation (5, 33).
Kra¨mer et al., however, linked the inhibition of IFN-regu-
lated gene expression directly to the acetylation of STAT1
(21–23, 38). They reported that the treatment of cells with
IFN- or low HDACi concentrations, namely, 30 nM TSA or
1.5 mM VPA, revealed the acetylation of STAT1 at Lys410 and
Lys413 (22, 23). Moreover, reference 22 reported that the
IFN-- and IFN--induced tyrosine phosphorylation of
STAT1 was suppressed at the same low HDACi concentra-
tions, which was explained by the recruitment of phosphatase
TC45 (41) by acetylated STAT1 (22). Consequently, STAT1
remained unphosphorylated in HDACi-treated cells. It accord-
ingly failed to accumulate in the nucleus of IFN-stimulated
cells, and it did not bind to the STAT1 recognition site on
DNA (termed the GAS element), such that IFN-induced gene
expression was lost. However, the inhibitory effects of HDACi
on STAT1 phosphorylation were reported to be reversed when
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cellular tyrosine phosphatases were inactivated by vanadate
treatment (22). As both HDACi and vanadate are not STAT1-
specific reagents, the authors produced a STAT1 mutant that
mimicked the acetylated state, i.e., KK410/413QQ (25), to link
HDACi-associated effects directly to the acetylation of STAT1
(22, 23). In perfect agreement with the results obtained with
HDACi and wild-type STAT1, the acetylation-mimicking mu-
tant was reported to remain unphosphorylated in IFN-treated
cells, it did not accumulate in the nucleus or bind DNA, and
hence it too was incapable of activating IFN target genes (22).
Importantly, according to the authors, the glutamine mutations
per se did not interfere with any of these STAT1 activities, as
they reported that the treatment of cells with vanadate or small
interfering RNA to inactivate tyrosine phosphatases com-
pletely rescued the phenotype of the acetylation-mimicking
mutant KK410/413QQ. Remarkably, when tyrosine phospha-
tase activity was suppressed, the IFN stimulation of cells was
shown to trigger Tyr701 phosphorylation of the mutant
STAT1, which now accumulated in the nucleus and bound to
GAS sites on DNA, culminating in the ability to activate IFN-
responsive genes. Thus, based on this consistent data set the
authors posited that the phosphorylation/dephosphorylation
cycle of STAT1 and, hence, interferon signaling was controlled
by the acetylation of residues 410 and 413 (22).
However, residues 410 and 413 are crucial for the NLS of
activated STAT1 (29), a fact that received no attention in these
studies. In agreement with general NLS requirements, lysines
in these positions facilitate the association of activated STAT1
with importin-, which is required for subsequent nuclear im-
port (26, 29, 32). Thus, we wondered how the acetylation of
NLS residues and the replacement of the lysines in positions
410 and 413 with glutamines to mimic acetylation affected
STAT1 nucleocytoplasmic mobility and IFN signaling. Table 1
summarizes published results concerning the effects of Lys410/
413 mutations on the tyrosine phosphorylation of STAT1, as
well as DNA binding and the nuclear import of the activated
molecule. As our results from the outset did not conform to the
model proposed by Kra¨mer et al., the key experiments pub-
lished in references 22 and 23 were repeated to evaluate the
biological significance of STAT1 acetylation. This exercise con-
firmed that the model presented by Kra¨mer et al. in references
22 and 23 is incorrect. We show here that neither IFN nor
HDACi triggered STAT1 acetylation. We show furthermore
that the treatment of cells with HDACi did not interfere with
the IFN-induced tyrosine phosphorylation of STAT1. In addi-
tion, the alleged acetylation-mimicking glutamine mutant of
STAT1, i.e., KK410/413QQ, is demonstrated to be defective
per se both in nuclear import and DNA binding. In further
stark contrast to the previously published results (22, 23), phos-
phatase inhibition could not rescue the nuclear import and
DNA binding deficiencies of acetylation-mimicking STAT1.
Finally, we have repeated the previously published experi-
ments with the original cDNAs encoding wild-type and acety-
lation-mimicking STAT1 that were provided by the authors of
the published studies (22, 23). The experiments with these
reagents did not reproduce the published results, whereas the
contradictory findings reported here were fully confirmed. In
sum, the claims that STAT1 acetylation controls immune re-
sponses by suppressing STAT1 tyrosine phosphorylation (22)
and regulates apoptosis by facilitating STAT1 binding to NFB
(23) were not upheld by the results presented here.
MATERIALS AND METHODS
Cell culture, cDNAs, and reagents. Human HeLa S3, U3A, and 293T cells
were grown at 37°C in a humidified 5% CO2 atmosphere in Dulbecco’s modified
Eagle’s medium (DMEM) containing 10% fetal calf serum (FCS; Sigma) and
antibiotics. Mammalian expression plasmids for wild-type (pSTAT1-GFP) and
mutant KK410/413EE (EE) STAT1 fused to green fluorescent protein (GFP)
have been described already (29); STAT1 was C-terminally Flag tagged. The
site-directed mutagenesis of pSTAT1-GFP (QuikChange; Stratagene) generated
mutants KK410/413QQ (QQ) and KK410/413RR (RR). Mutations were verified
by DNA sequencing. Transient transfections were carried out using Lipo-
fectamine Plus (Invitrogen) as described previously (3). Unless stated otherwise,
the treatment of cells was with human IFN- (103 U/ml; Calbiochem), human
IFN- (20 ng/ml; Calbiochem), 1.5 mM VPA (Sigma), 30 nM TSA (Sigma), and
1 mM pervanadate. Mammalian expression constructs published by Kra¨mer et al.
(22) encoding the wild type and QQ mutant of STAT1 were requested from the
authors in February 2010, and dried cDNA was obtained on 14 October 2010.
DNA was extracted with Tris-EDTA (TE) and was used to transform DH5
bacteria. Single bacterial colonies were amplified, and plasmid DNA was purified
using the Qiagen Maxiprep protocol. The resulting cDNAs were of comparable
quality, as judged by readings of the optical density at 260 and 280 nm, which
were 1.92 for STAT1-QQ and 1.87 for STAT1-WT, respectively. Clones of both
plasmids were partially sequenced in house using the Big Dye sequencing pro-
tocol (Applied Biosystems), followed by capillary electrophoresis using a com-
mercial source (Gene Services Nottingham).
Quantitative Western blotting and immunoprecipitation. Cell extractions
were performed in whole-cell extraction buffer (50 mM Tris-HCl, pH 7.4, 280
mM NaCl, 5 mM EDTA, 2 mM EGTA, 10% [vol/vol] glycerol, 50 mM NaF, 10
mM glycerol phosphate, 1 mM sodium pervanadate [VO43], 0.2% [vol/vol]
NP-40, 3 mM dithiothreitol [DTT], 0.1 mM phenylmethylsulfonyl fluoride
[PMSF], and Complete [Roche] protease inhibitors) for 30 min on ice. Soluble
components were separated by centrifugation at 14,000  g for 15 min at 4°C and
used for immunoprecipitation (30) and Western blotting. Western blotting en-
tailed the labeling of primary antibodies with IRdye800-conjugated secondary
immunoglobulin (Licor Biosciences). Control readings were obtained with di-
luted cell extracts to confirm that signal intensities were within the linear range.
Where the presence of multiple proteins/protein modifications was examined,
this was done consecutively for each antibody using the same blot. Bound anti-
bodies were stripped off nitrocellulose membranes by incubation for 30 min twice
TABLE 1. Functional characterization of wild-type STAT1 and
STAT1 variants mutated in positions 410 and 413
STAT1
construct
Functional statusa
Reference(s)
pTyr701 DNAbinding
pTyr701 STAT1
nuclear import
WT   
RR    22
QQ    22
EE    29
AA    26, 28
a , Functionality; , loss of functionality.
FIG. 1. Functional domains (demarcated by residue number) and
nuclear localization signal sequence (pNLS) of STAT1 (29). N, N
domain; CC, coiled-coil domain; LD, linker domain; SH2, src homol-
ogy 2 domain; TAD, transactivation domain.
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in stripping buffer (25 mM glycine, 2% SDS, pH 2) at 65°C. Primary antibodies
were purchased from Cell Signaling (anti-pTyr701 STAT1, order no. 9171 and
anti-acetylated lysine, order no. 9441 [formerly sold by NEB]), Santa Cruz
(anti-STAT1, C24, E23, anti-simian virus 40 [SV40] T antigen [Pab 108], order
no. sc-148), Abcam (anti-acetyl-histone 3 and H3[lys9]), and Sigma (anti-FLAG
and anti--actin).
Immunofluorescence microscopy. Cells were fixed with methanol at 20°C,
washed in phosphate-buffered saline (PBS), and blocked with 20% (vol/vol)
FCS–PBS. Samples were incubated overnight with either anti-STAT1 antibody
(C24; dilution, 1:6,000) or anti-pTyr701 STAT1 antibody diluted 1:250 in 20%
(vol/vol) FCS–PBS. After three washes with PBS, the cells were incubated with
appropriate species-specific affinity-purified Cy3-conjugated immunoglobulins
(Jackson Research) in 20% (vol/vol) FCS–PBS. A Leica DMLB microscope was
used as described previously (3).
EMSA. For electrophoretic mobility shift assay (EMSA), U3A cells (1.8  105
to 2  105) were transiently transfected. Thirty-six h later, the cells were left
untreated or were treated as described in the figure legends. After two washes
with ice-cold PBS, the cells were incubated on ice for 5 min in 70 l cytoplasmic
extraction buffer (10 mM KCl, 1 mM EDTA, 20 mM HEPES-NaOH, pH 7.4, 0.1
mM sodium pervanadate, 1.5 mM MgCl2, 10% [vol/vol] glycerol, 1 mM DTT,
Complete protease inhibitors, 0.2% [vol/vol] NP-40, and 0.1 mM PMSF), fol-
lowed by centrifugation for 20 s at 4°C and 14,000  g. The supernatant (cyto-
plasmic extract) was isolated and kept on ice. The pellet was resuspended in 70
l nuclear extraction buffer (420 mM KCl, 1 mM EDTA, 20 mM HEPES-NaOH,
pH 7.4, 0.1 mM pervanadate, 1.5 mM MgCl2, 20% [vol/vol] glycerol, 1 mM DTT,
Complete protease inhibitors, and 0.1 mM PMSF), and incubated for 30 min on
ice. After centrifugation for 15 min at 4°C and 14,000  g, the nuclear extract was
isolated and combined with the corresponding cytoplasmic extract. A Bradford
assay (Bio-Rad) was used to confirm equal protein concentrations for the dif-
ferent extracts. Five micrograms of extracted protein was incubated in a 14-l
reaction mix {containing 1 mg/ml bovine serum albumin (BSA), 1 mM DTT, 2
g poly(dI-dC), 20 mM HEPES-NaOH, pH 7.9, 40 mM KCl, 1 mM MgCl2, 0.4
mM EDTA, 0.1 mM EGTA, 4% (vol/vol) Ficoll, and 1 nM double-stranded
[-32P]CTP-labeled DNA probe} for 20 min at room temperature. The DNA
probe (5	-TGATTTCCCCGAAATGACGGC-3	 with 5	-TGAG-3	 overhangs at
the 5	 end of both strands) harbored a single GAS site (underlined) from the
IRF-1 gene promoter (35). For the immune detection of DNA-bound STAT1
(supershift), anti-STAT1 antibody (C24) was added to the reaction mix (1 l).
DNA-protein complexes were resolved at 4°C and 400 V on 4.7% nondenaturing
polyacrylamide gels using Tris-borate-EDTA buffer (140 mM Tris-HCl, pH 8.0,
22 mM boric acid, and 2 mM EDTA). After a running time of 90 min, gels were
dried; radioactivity was detected and quantified by phosphorimaging (FLA-3000;
Fujifilm).
RESULTS AND DISCUSSION
Our analyses of the effects of lysine acetylation on the func-
tion of STAT1 started with an attempt to confirm STAT1
acetylation. The previously published experiments were done
with several different cell lines; however, crucial experiments
were performed with 293T cells, which express SV40 large T
antigen (22, 23). Because SV40 large T antigen binds to cel-
lular factors, including the transcriptional coactivators p300
and CBP (2), and CBP is responsible for the acetylation of
STAT1 according to the published results (22, 23), we first
confirmed by Western blotting that our 293T cells, but not
primary and spontaneously immortalized mouse embryonic fi-
broblasts (MEF), expressed SV40 large T antigen. Figure 2A
shows that this was indeed the case. We then stimulated 293T
cells with IFN- for 3 h as described by Kra¨mer et al. (see Fig.
1A of reference 22), followed by the immunoprecipitation of
the endogenous STAT1 from whole-cell extracts and the prob-
ing of the immunoprecipitates with antiacetyllysine-specific an-
tibody. Additionally, 293T cells were treated with 1.5 mM VPA
for 24 h, either alone or in conjunction with subsequent IFN-
for 3 h, as this was described to boost the acetylation of STAT1
(see Fig. 6A of reference 23). However, despite repeated at-
tempts, in our hands neither approach gave a signal for acety-
lated STAT1 (Fig. 2B). Human fibrosarcoma 2fTGH cells are
another cell line that was reported to harbor acetylated STAT1
upon stimulation with IFN- (see Fig. 6F of reference 23). We
thus used 2fTGH-derived U3A cells (31), which lack STAT1
expression, and reconstituted them with Flag-tagged STAT1.
However, immunoprecipitated Flag-tagged STAT1 did not
show reactivity with acetyllysine antibody irrespective of IFN-
FIG. 2. STAT1 lacks immunoreactivity with antiacetyllysine antibody irrespective of treatment with interferon and HDACi. (A) Whole-cell
extracts from 293T cells used in this study (lane 1), control 293T cells obtained from LGC Standards (ATCC CRL-1573) (lane 2), primary MEFs
(lane 3), and a spontaneously immortalized MEF cell line (lane 4). Shown are Western blotting (IB) results with anti-SV40 T antigen antibody and
the reprobing with anti--actin antibody. (B) 293T cells were incubated with 1.5 mM VPA () or left untreated for 24 h, followed by the addition
of 1,000 U/ml IFN- for 3 h where indicated (). STAT1 was immunoprecipitated (IP) from whole-cell extracts, followed by Western blotting.
Shown are the consecutive probings with antiacetyllysine antibody (upper) and anti-STAT1 antibody (lower). (C) U3A cells were transfected with
vector encoding C-terminally Flag-tagged STAT1. Twenty-four hours later, cells were stimulated with 1,000 U/ml IFN- for 3 h (), followed by
whole-cell extraction and immunoprecipitation using anti-Flag antibody. Shown are Western blotting results for the precipitates probed consec-
utively with antiacetyllysine antibody and anti-STAT1 antibody. (D) 293T cells were left untreated or were treated with VPA or TSA for 24 h as
indicated. Shown are Western blotting results for whole-cell extracts probed with anti-acetyl-Lys9 histone 3 antibody and subsequently reprobed
with anti--actin antibody.
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treatment (Fig. 2C). To verify that the HDACi were active at
the concentrations used, we performed control reactions with
acetylated histone 3-specific antibody, which demonstrated in-
creased histone 3 acetylation in 293T cells upon treatment with
TSA or VPA (Fig. 2D). As STAT1 acetylation has been dem-
onstrated exclusively by immune reactivity but was not vali-
dated to date by another method, e.g., mass spectrometry, we
could not decide whether this outcome reflected the absence of
acetylated STAT1 or was due to unreliable immunodetection.
To our knowledge, STAT1 acetylation has been observed in
two other instances, but the data quality was not definitive (16,
40), and according to those studies there was no impairment of
STAT1 phosphorylation associated with acetylation. A third
study on STAT1 acetylation reported a lack of immunodetect-
able STAT1 lysine acetylation in B-cell lines irrespective of
treatment with IFN- or TSA (27). Our failure to detect acety-
lated STAT1 is unlikely to be explained by antibody differ-
ences, as preparations of the same commercially available
acetyllysine antibody were used in the present and the earlier
studies (22, 23). Another factor relevant for successful detec-
tion is the abundance of acetylated STAT1 in cells, which to
our knowledge has not been quantified. However, Kra¨mer et
al. report that the target of acetylation is phosphorylated
STAT1 (22, 23), which makes up 30 to 40% of STAT1 in
interferon-stimulated cells (43). According to reference 22,
acetylation is required to recruit phosphatase TC45 to the
activated STAT1. If we assume that at least one monomer of
each phosphodimer needs to be acetylated for efficient phos-
phatase recruitment, it is safe to presume that in IFN-stimu-
lated cells about 10 to 20% of STAT1 molecules are acetylated
at steady state. Contrary to labile posttranslational modifica-
tions, like the SUMO conjugation of STAT1, which is difficult
to preserve (12), lysine acetylation is efficiently stabilized by
deacetylase inhibitors according to the published experiments
(22, 23). Moreover, treatment with deacetylase inhibitors was
reported to completely suppress the IFN-induced phosphory-
lation of STAT1 (see Fig. 1E in reference 22), suggesting that
the quantitative acetylation of STAT1 is readily achieved un-
der these conditions. Thus, it is reasonable to assume that a
large fraction, probably in excess of 30 to 40% of the cellular
STAT1 content, should have been acetylated in our experi-
ments. Therefore, a very small modified and, hence, difficult-
to-detect fraction of acetylated STAT1 is an unlikely explana-
tion for the lack of antiacetyllysine immunoreactivity.
We therefore focused on the reported consequences of
STAT1 acetylation, namely, the inhibition of IFN-- and IFN-
-induced STAT1 Tyr701 phosphorylation. It was reported
that a 24-h pretreatment of 293T cells with HDACi VPA (1.5
mM) or TSA (30 nM) precludes the subsequent 20-min IFN-
-induced tyrosine phosphorylation of STAT1 (see Fig. 1E in
reference 22). To attempt to reproduce this experiment, 293T
cells were left untreated or were treated with HDACi VPA
(1.5 mM) or TSA (30 nM) for 24 h, followed by stimulation
with IFN- for 20 min as described above. IFN treatment
alone caused the expected Tyr701 phosphorylation of STAT1
(Fig. 3A). However, in stark contrast to the published results,
pretreatment with HDACi TSA (30 mM) or VPA (1.5 mM)
left the IFN--induced tyrosine phosphorylation of STAT1
undiminished (Fig. 3A). Three quantitative Western blotting
experiments generated no statistically significant differences
regarding IFN--induced Tyr701 phosphorylation between un-
treated and HDACi-treated cells (Fig. 3A). We additionally
studied the effects on STAT1 phosphorylation of increasing
concentrations of VPA (Fig. 3B), TSA (Fig. 3C), or another
HDACi, sodium butyrate (NaBu) (Fig. 3D). Even at more than
10-fold higher than published HDACi concentrations, STAT1
was strongly phosphorylated in response to IFN-, not at all
resembling the complete loss of IFN-- or -induced Tyr701
phosphorylation reported in Fig. 1E and data not shown of
reference 22. We thus inferred that low HDACi concentrations
FIG. 3. STAT1 activation continues in the presence of histone deacetylase inhibitors. (A) 293T cells were left untreated or were treated with
VPA or TSA. After 24 h the cells were stimulated for 20 min with 1,000 U/ml IFN- where indicated (), followed by whole-cell extraction. Shown
are representative Western blotting (IB) results of consecutive probing with anti-pTyr701 STAT1 antibody and anti-STAT1 antibody. The positions
of STAT1 (St1) and its C-terminally truncated splice variant STAT1 (St1) are indicated. Note that the anti-STAT1 antibody C24 used here
does not recognize STAT1. The bar diagram on the right combines the data from three independent experiments. Shown are the means and
standard deviations for the specific tyrosine phosphorylation of STAT1 in IFN-stimulated cells, as determined by quantitative Western blotting.
The mean value for untreated cells was set to 100. For statistical analysis, a one-way analysis of variance test was performed. n.s., not significant.
(B) HeLa cells were incubated with increasing concentrations of VPA as indicated. Twenty-four hours later, cells were stimulated with 20 ng/ml
IFN- for 1 h where indicated (). Tyr701 phosphorylation of STAT1 was assessed by Western blotting as described for panel A. (C) Cells were
treated as described for panel B, but 293T cells were used and treated with TSA. Note that anti-STAT1 antibody E23 was used here, which detects
both STAT1 splice variants. (D) Cells were treated as described for panel C, except that Na-butyrate, another HDACi, was used.
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did not alter the activation of STAT1. This conclusion agrees
with numerous previous studies, which reported the un-
changed or even prolonged tyrosine phosphorylation of
STAT1 at low HDACi concentrations similar to those used
here (5, 33, 36).
We next studied the IFN-induced activation of the acetyla-
tion-mimicking mutant of STAT1, KK410/413QQ (termed
QQ). This mutant was reported to remain unphosphorylated in
U3A cells after 1 h of IFN- treatment, thus justifying its
characterization as an acetylation-mimicking STAT1 variant
(see Fig. 1G in reference 22). We repeated this experiment in
U3A cells as described previously (22). However, in contrast to
the published results, we found robust phosphorylation of this
STAT1 mutant (Fig. 4A). We also analyzed the Tyr701 phos-
phorylation of additional STAT1 variants, where the lysine
residues at positions 410 and 413 were changed to arginine
(RR) or glutamate (EE). Three independent quantitative im-
munoblotting experiments were done, and the specific tyrosine
phosphorylation of the STAT1 variants was determined. This
experiment demonstrated that there were no statistically sig-
nificant phosphorylation differences between wild-type STAT1
and any of these mutants (Fig. 4A). Specifically, the tyrosine
phosphorylation of STAT1 KK410/413QQ was not weaker
than that of the wild type. As a negative phosphorylation con-
trol, we included a Tyr701-to-phenylalanine mutant in this
analysis (37). Strong tyrosine phosphorylation of the alleged
acetylation-mimicking mutant was seen in response to IFN-
(Fig. 4B), again in clear contradiction to results reported pre-
viously (22). We thus concluded that the alleged acetylation-
mimicking mutant does not differ from wild-type STAT1 re-
garding tyrosine phosphorylation.
We then examined the DNA binding of the acetylation-
mimicking STAT1 mutant KK410/413QQ, which was shown to
bind to GAS sites (see Fig. 5F in reference 22). However, to
reveal the mutant’s DNA binding activity, previously cells
needed to be treated with a phosphatase inhibitor, e.g., vana-
date (22). According to the authors, this treatment was re-
quired to overcome the excessive dephosphorylation caused by
the phosphatase recruitment of the pseudoacetylated STAT1.
The QQ mutant therefore bound to DNA in the presence of a
tyrosine phosphatase inhibitor (see Fig. 5F in reference 22) but
not in its absence (see Fig. 5F, S1H, and S2D in reference 22).
According to the published data, these results establish that
acetylation-mimicking STAT1 KK410/413QQ, if phosphory-
lated, is capable of binding to GAS-containing DNA. The
dependence of DNA binding and transcriptional activity on
phosphatase inhibition (as shown in Fig. 5E in reference 22) is
of pivotal importance for the proposed phosphorylation-acety-
lation switch model. For one thing, it confirms the acetylation-
mimicking activity of the QQ mutant. More crucially, it repre-
sents the cornerstone of the proposed model on which the
authors rest their central conclusion that acetylation inhibits
STAT1 signaling by facilitating the recruitment of phosphatase
activity to the activated transcription factor (Table 1).
Before we report the results of experiments evaluating the
validity of this set of published data, we first need to comment
on details of the methodology that was used to demonstrate
STAT1 DNA binding in the published study (22). To evaluate
FIG. 4. Side chain chemistry of residues 410 and 413 is irrelevant for STAT1 phosphorylation, but positive charges in these positions are
required for sequence-specific DNA binding. (A, B) U3A cells were transiently reconstituted with the STAT1 wild type (WT), mutant KK410/
413QQ (QQ), mutant KK410/413EE (EE), mutant KK410/413RR (RR), and mutant Tyr701Phe (YF). Forty-eight hours after transfection, cells
were treated with 1,000 U/ml IFN- (A) or 20 ng/ml IFN- (B) for 1 h where indicated (), followed by whole-cell extraction. Shown are
representative Western blotting (IB) results obtained by consecutive probing with anti-pTyr701 STAT1 antibody and anti-STAT1 antibody (C24).
The bar diagrams combine the data from three independent experiments each. Shown are the means and standard deviations for the specific
tyrosine phosphorylation of STAT1 in IFN-stimulated cells, as determined by quantitative Western blotting. The mean value for wild-type cells
(A) or QQ mutant cells (B) was set to 100. For statistical analysis, one-way analysis of variance tests were performed. n.s., not significant. (C) U3A
cells were transfected with the indicated STAT1 constructs described for panel A. Thirty-six h later, consecutive cytoplasmic and nuclear cell
extractions were done as described in Materials and Methods. Shown are EMSA results using [-32P]CTP-labeled DNA probe containing the
IRF-1 GAS binding site. The binding reaction mixture analyzed in lane 10 contained anti-STAT1 antibody. Free probe (*), STAT1-DNA complex
(arrow), and the antibody-bound STAT1-DNA complex (bracket) are indicated.
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the sequence-specific DNA binding of a protein, the sequence
of the DNA must be known. “GAS consensus oligonucleo-
tides” and “GAS sequences” are mentioned numerous times in
reference 22, yet the only precise information about the actual
GAS sequence that was used can be found in the legend to Fig.
S1H, where it is stated, “A pulldown assay with a biotinylated
GAS oligonucleotide (ABCD-assay) was used to detect
STAT1-DNA binding. The oligonucleotide represents two pal-
indromic TCC half-sites, contacted by the DNA binding do-
mains of an activated STAT1 dimer.” This statement does not
fully clarify the issue, since GAS sites are nonameric (TTCN
NNGAA) and thus are not represented by two palindromic
TCC half sites (9). Nonetheless, this and other statements
suggest that the authors wanted to study the DNA binding of
dimers of activated STAT1. However, instead of treating cells
with IFN-, which is the most potent and specific STAT1-
activating stimulus, IFN- was used to assess DNA binding.
IFN- stimulation gives rise predominantly to STAT1/STAT2
heterodimers that bind together with another protein, IRF-9,
to an unrelated DNA site (9, 15), such that relatively few
STAT1 dimers capable of GAS binding remain. These incom-
plete descriptions and the very difficult-to-interpret study de-
sign precluded the exact repetition of the experiments as pub-
lished. We decided therefore to follow established procedures
that generate unambiguous results to examine the DNA bind-
ing of dimers of wild-type and mutant STAT1, respectively.
This included the use of electrophoretic mobility shift assay
(EMSA) rather than precipitation methods like the ABCD
assay, as the latter uses denaturing conditions to resolve DNA
binding complexes, thus destroying information on the size and
composition of the DNA-associated protein complexes. This
limitation makes precipitation assays less useful for studying
sequence-specific DNA binding proteins. As the probe, we
used radiolabeled DNA containing a single high-affinity
STAT1 binding site, the GAS element of the IRF-1 promoter
(35). Also, cells were treated with IFN- to generate large
quantities of activated STAT1 dimers, which facilitates analy-
ses of GAS-specific DNA binding activity.
Using whole-cell extracts from U3A cells transiently recon-
stituted with STAT1 variant proteins as described previously
(22), we observed a single protein-DNA complex for wild-type
STAT1 (Fig. 4C, lanes 1 and 2) that was reactive with STAT1
antibody (lane 10), indicating that the DNA binding complex
contained STAT1 as expected. We then tested the DNA bind-
ing of the acetylation-mimicking mutant KK410/413QQ. Al-
though abundant activated STAT1 was present in the extracts
(Fig. 4B), there was no binding of STAT1 QQ to GAS-con-
taining DNA (lanes 3 and 4). The identical negative outcome
was seen with mutant KK410/413EE (lanes 5 and 6), which we
had shown previously to dimerize yet to be defective in DNA
binding (29), while the arginine mutant KK410/413RR re-
tained binding to the GAS site (lanes 7 and 8). These results
demonstrated that positive charges in positions 410 and 413
are indispensable for the binding of STAT1 to its recognition
site on DNA.
Lysines 410 and 413 are part of the nuclear import signal for
activated STAT1 (29). However, little is known about how the
acetylation of lysine residues or their charge-neutralizing mu-
tation affects NLS activity. It was reported for STAT1 that the
charge-neutralizing mutation of lysines 410 and 413 to glu-
tamine does not per se impair the nuclear import of the phos-
phorylated protein (see Fig. 5D in reference 22). We therefore
transiently reconstituted U3A cells with wild-type or mutant
STAT1 and used immunofluorescence microscopy to observe
the activation and intracellular distribution of STAT1 in re-
sponse to IFN- stimulation. Wild-type STAT1 showed the
well-known IFN--induced activation and concomitant nuclear
accumulation (42) (Fig. 5A). The acetylation-mimicking QQ
mutant showed similarly strong IFN--induced activation, sub-
stantiating our Western blotting results but again contradicting
the published experiments (see Fig. 1G in reference 22). Im-
portantly, however, the phosphorylated mutant did not accu-
mulate in the nucleus but rather stayed in the cytoplasm (Fig.
5A), in further contradiction of the published results (see Fig.
5C and D in reference 22). The glutamate mutation of residues
410 and 413 also precluded nuclear accumulation, and the
activated protein stayed in the cytoplasm, whereas the arginine
mutation of these positions did not impair STAT1 nuclear
accumulation (Fig. 5A). We additionally tested whether treat-
ment with vanadate could overcome the nuclear import defect
of the glutamine mutants of STAT1, as shown in Fig. 5D of the
earlier study (22). However, this was not the case, as the phos-
phorylated glutamine as well as the glutamate mutants re-
mained in the cytoplasm (Fig. 5A). Control experiments veri-
fied the tyrosine phosphatase-inhibiting activity of the
vanadate preparation used here. Vanadate measurably pro-
longed the IFN-induced nuclear accumulation of wild-type
STAT1 (Fig. 5B), which is explained by the inability of ty-
rosine-phosphorylated STAT1 to return to the cytoplasm (30).
When this experiment was performed in HeLa cells using
IFN- stimulation, the same outcome was observed, namely,
strong phosphorylation yet defective nuclear import of the
acetylation-mimicking STAT1 QQ mutant, while the phos-
phorylated arginine mutant retained nuclear import (Fig. 5C).
Interestingly, in the presence of H2O2, which was used in this
experiment in conjunction with pervanadate to inhibit tyrosine
phosphatase activity, phosphorylated STAT1 formed paracrys-
tals. This phenomenon is explained by the concomitant H2O2-
dependent inactivation of STAT1 SUMO conjugation (12). Of
note, the QQ mutant formed paracrystals in the cytoplasm,
providing corroborating evidence for the efficient phosphory-
lation and loss of nuclear import. We thus concluded that
positive charges in positions 410 and 413 are required both for
sequence-specific DNA binding and the nuclear import of ac-
tivated STAT1. These results agree with data independently
obtained for STAT1 (28), Max transcription factor (14), and
the Rothmund-Thomson-syndrome gene product RECQL4
(11), whose nuclear import is precluded by charge-neutralizing
replacements with glutamine or alanine of lysine residues re-
quired for NLS functioning.
Given the complete lack of agreement with the reported
results, we requested the original mammalian expression vec-
tors encoding wild-type STAT1 and the acetylation-mimicking
mutant that were used in the published studies (22, 23). DNA
sequencing of 
100 bp upstream and 
800 bp downstream of
the STAT1 coding sequence revealed no differences between
the two constructs (data not shown), and they matched the
sequence of pcDNA3.1 TOPO vector (Invitrogen), thus con-
firming the published information (23). The wild-type STAT1-
encoding sequence was identical to the GenBank entry
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NM_007315 for human STAT1. The cDNA of STAT1 acety-
lation-mimicking mutant QQ showed the expected (single-
base) changes of codons 410 and 413 resulting in mutations to
glutamine (see Fig. S1 in the supplemental material). We
found three additional single-base changes affecting codons
636, 740, and 742, one of which resulted in the mutation of the
STAT1 protein at Lys6363Arg (Fig. 6A; also see Fig. S1 in the
supplemental material). Residue 636 is situated in the SH2
domain and is part of a conserved antiparallel -sheet that
constitutes the core of this domain (6), but subsequent exper-
iments showed that the protein mutated in position 636 was
expressed in mammalian cells, indicating that this amino acid
change did not alter protein structure. U3A cells then were
transfected with these constructs to determine tyrosine phos-
phorylation and the nuclear translocation of the published
proteins. As shown in Fig. 6B, quantitative Western blotting
demonstrated that wild-type STAT1 and the acetylation mu-
tant QQ both were equally well tyrosine phosphorylated, with
no statistically significant differences between them. Similarly,
immunofluorescence microscopy confirmed both the undimin-
ished tyrosine phosphorylation of acetylation-mimicking
STAT1 KK410/413QQ in response to IFN- and its inability to
accumulate in the nucleus (Fig. 6C). Thus, irrespective of the
origin of the reagents used, the same results were obtained.
In summary, the experiments reported here generated no
evidence that the stimulation of cells with interferons or treat-
ment with HDACi result in the acetylation of STAT1. How-
ever, we cannot formally rule out this possibility, nor do we
exclude that STAT1 might be acetylated in circumstances
other than those investigated. That said, the results presented
FIG. 5. Acetylation-mimicking STAT1 mutant is phosphorylated but not imported in the nucleus. (A) U3A cells were transiently reconstituted
with GFP-tagged wild-type STAT1 (WT), mutant KK410/413QQ (QQ), mutant KK410/413EE (EE), or mutant KK410/413QRR (RR). After 48 h
the cells were treated with 1,000 U/ml IFN- for the indicated times. Where indicated (VO4
3), cells were pretreated for 45 min with 1 mM
pervanadate before the addition of IFN- for another 60 min. Shown are immunofluorescence images depicting the localization of STAT1
(determined by GFP epifluorescence) and the localization of phosphorylated STAT1 (pSTAT1), determined by labeling with anti-pTyr701-STAT1
antibody. (B) U3A cells were transfected with GFP-tagged wild-type STAT1. Forty-eight hours later, cells were treated for 0 to 6 h with 1,000 U/ml
IFN- alone or together with 1 mM pervanadate (VO4
3). Shown are GFP epifluorescence micrographs that depict the distribution of STAT1.
(C) HeLa cells were transiently transfected with GFP-tagged wild-type STAT1 (WT) or mutant QQ or RR as indicated. After 36 h the cells were
left untreated or were treated for 60 min with IFN- (20 ng/ml). Where indicated (VO4
3/H2O2), cells were pretreated for 45 min with 0.8 mM
pervanadate and 0.2 mM H2O2 prior to the addition of IFN-. Shown are immunofluorescence images depicting the localization of STAT1
(determined by GFP epifluorescence) and the localization of phosphorylated STAT1 (pSTAT1), determined by labeling with anti-pTyr701-STAT1
antibody. Nuclei were labeled with Hoechst dye. Note the appearance of STAT1 paracrystals in the presence of H2O2. Bars, 10 m.
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here conclusively exclude the possibility that STAT1 signaling
is regulated by a phosphorylation-acetylation switch as pro-
posed by Kra¨mer et al. (22). The proposed switch mechanism
is based on the experimental demonstration (22) that the treat-
ment of cells with HDACi prevents the IFN-induced phos-
phorylation of STAT1, and that the resulting inhibition of
STAT1 signaling can be overcome by the inactivation of cel-
lular phosphatases. We disprove this claim by showing that the
treatment of cells with HDACi results in the undiminished
phosphorylation of STAT1. Validation of the model proposed
in reference 22 furthermore hinges on the use of a single
reagent, namely, the supposed acetylation-mimicking glu-
tamine 410/413 mutant of STAT1. It was reported that glu-
tamine mutations of residues 410 and 413 prevented IFN-
induced phosphorylation of STAT1, and that the resulting
inhibition of STAT1 signaling caused by these mutations could
be overcome by the inactivation of cellular phosphatases (22).
We show here that the IFN-induced phosphorylation of the
glutamine mutant of STAT1 is not diminished, which disproves
the alleged resistance of this mutant to IFN stimulation and
hence invalidates its characterization as an acetylation-mim-
icking STAT1 variant. In addition, we show that the nuclear
import and sequence-specific DNA binding of the glutamine
mutant both are inactivated, which prevents this protein from
functioning as a signal transducer and activator of transcrip-
tion, i.e., STAT1. The invalidated so-called acetylation-mim-
icking glutamine mutant is pivotal for Kra¨mer et al. to dem-
onstrate that acetylated STAT1 controls both IFN signaling
and cell death. At present, the claims put forth in references 22
and 23 were found to be without experimental justification, as
are attempts to link the protective effects of histone deacety-
lase inhibitors against cancer and inflammation to the Lys410/
Lys413 acetylation of STAT1 (4, 10, 17, 18, 34, 44). As re-
ported here, despite of our best attempts to reproduce exactly
the experiments of references 22 and 23, we found no experi-
mental confirmation of the results presented there. We are
unable to provide a scientifically acceptable explanation for the
complete dichotomy of our findings from those reported by
Kra¨mer et al.
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FIG. 6. Published results (22, 23) are not reproducible using published reagents. (A) DNA sequencing of the published constructs reveals an
undisclosed amino acid exchange in position 636. (B) U3A cells were transiently transfected with the published constructs encoding wild-type
STAT1 (WTG&D) or mutant KK410/413QQ (QQG&D). After 36 h, the cells were left untreated or were stimulated with 1,000-U/ml IFN- for 1 h,
followed by whole-cell extraction. Shown are representative Western blotting (IB) results obtained by consecutive probing with anti-pTyr701-
STAT1 antibody, anti-STAT1 antibody (C24), and anti--actin antibody. The bar diagram combines the data from three independent experiments.
Shown are the means and standard deviations for the specific tyrosine phosphorylation of STAT1 before and after IFN stimulation, as determined
by quantitative Western blotting. The mean value for IFN-stimulated wild-type cells was set to 100. For statistical analysis, a t test was applied. n.s.,
not significant. (C) U3A cells were transfected as described for panel B. After 36 h, cells were left untreated or were treated with 1,000-U/ml IFN-
for 60 min. Where indicated (VO4
3), IFN was added after a 45-min pretreatment with 1 mM pervanadate. After fixation and permeabilization
in ice-cold methanol, cells were labeled with anti-STAT1 antibody (C24, upper) or anti-pTyr701-STAT1 antibody (lower), followed by Cy3-labeled
secondary antibody. Shown are immunofluorescence micrographs depicting the localization of total STAT1 (upper) and the localization of
Tyr701-phosphorylated STAT1 (lower). Nuclei were stained with Hoechst dye (Hoechst). Bar, 10 m.
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